UK Watchdog Calls for New AI Regulations in Healthcare

New Regulatory Framework Proposed

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has published 44 recommendations to update its policies regarding artificial intelligence (AI) products in healthcare. This move comes as AI use in the NHS and other healthcare settings is expected to become routine, according to MHRA chief Lawrence Tallon.

Key Recommendations

The proposed recommendations include continuously monitoring AI products and removing them from regulatory approval if they malfunction or become less effective. Patients would gain the right to know if AI is involved in their care and have access to information about the products. The framework also suggests the power to penalize AI product developers for failing to meet required standards and an 'L plate' system for supervised trials of new AI models.

Addressing Outdated Regulations

Tallon noted that the current medical devices regulatory framework primarily dates from a period focused on products like hip replacements and stethoscopes. While these guidelines may suffice for simple AI products, they are inadequate for more complex, adaptive AI models that change after authorization as new data is fed in. This continuous adaptation, or 'drift,' presents a unique regulatory challenge.

Global Challenge

Regulating AI is acknowledged as a global challenge, with no single country currently possessing a fully effective framework. The MHRA's efforts aim to establish a robust system that maintains patient trust and confidence as AI integration in healthcare expands.